AR065579A1 - Mejoras en composiciones medicinales o relativas a las mismas - Google Patents

Mejoras en composiciones medicinales o relativas a las mismas

Info

Publication number
AR065579A1
AR065579A1 ARP080100880A ARP080100880A AR065579A1 AR 065579 A1 AR065579 A1 AR 065579A1 AR P080100880 A ARP080100880 A AR P080100880A AR P080100880 A ARP080100880 A AR P080100880A AR 065579 A1 AR065579 A1 AR 065579A1
Authority
AR
Argentina
Prior art keywords
naloxone
buprenorphine
composition
dosage form
same
Prior art date
Application number
ARP080100880A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of AR065579A1 publication Critical patent/AR065579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP080100880A 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas AR065579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703968A GB2447016A (en) 2007-03-01 2007-03-01 Buprenorphine/naloxone compositions

Publications (1)

Publication Number Publication Date
AR065579A1 true AR065579A1 (es) 2009-06-17

Family

ID=37965735

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100880A AR065579A1 (es) 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas

Country Status (16)

Country Link
US (1) US20110046172A1 (enExample)
EP (1) EP2129380A1 (enExample)
JP (2) JP2010520186A (enExample)
KR (1) KR20090117891A (enExample)
CN (1) CN101626766B (enExample)
AR (1) AR065579A1 (enExample)
AU (1) AU2008220574A1 (enExample)
BR (1) BRPI0807908A2 (enExample)
CA (1) CA2678582A1 (enExample)
CL (1) CL2008000606A1 (enExample)
GB (1) GB2447016A (enExample)
MX (1) MX2009009131A (enExample)
PE (1) PE20090168A1 (enExample)
TW (1) TWI451868B (enExample)
WO (1) WO2008104738A1 (enExample)
ZA (1) ZA200905664B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9277748B2 (en) * 2010-03-12 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Agonist/antagonist compositions and methods of use
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
MX352959B (es) * 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
CN103690495B (zh) * 2013-12-19 2015-04-08 贵州景峰注射剂有限公司 注射用盐酸纳洛酮的冷冻干燥方法
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
CN101626766A (zh) 2010-01-13
KR20090117891A (ko) 2009-11-13
CA2678582A1 (en) 2008-09-04
CL2008000606A1 (es) 2008-10-03
HK1139871A1 (en) 2010-09-30
US20110046172A1 (en) 2011-02-24
TW200843773A (en) 2008-11-16
ZA200905664B (en) 2010-10-27
TWI451868B (zh) 2014-09-11
WO2008104738A1 (en) 2008-09-04
GB0703968D0 (en) 2007-04-11
AU2008220574A1 (en) 2008-09-04
EP2129380A1 (en) 2009-12-09
CN101626766B (zh) 2013-07-10
JP2014196325A (ja) 2014-10-16
JP2010520186A (ja) 2010-06-10
PE20090168A1 (es) 2009-03-19
MX2009009131A (es) 2009-09-03
BRPI0807908A2 (pt) 2014-06-17
GB2447016A (en) 2008-09-03

Similar Documents

Publication Publication Date Title
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
AR031682A1 (es) Composiciones farmaceuticas
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
JP2010520186A5 (enExample)
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR063109A1 (es) Terapias topicas para la mucositis oral y otras afecciones
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
JP2011500781A5 (enExample)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR063782A1 (es) Parche y metodo transdermico para emesis
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
JP2010520184A5 (enExample)
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
BRPI0409380A (pt) composições farmacêuticas
JP2016505050A5 (enExample)
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal